Biological targets do not operate in isolation. A protein that has functional relevance in tumor biology is embedded in a network of pathway relationships: upstream regulators, downstream effectors, co-activators, feedback inhibitors, and compensatory nodes that activate when the primary target is perturbed. How a target ranks in evidence depends partly on that network context, and evaluating the target outside of it produces an incomplete picture.
This is one of the more practically important aspects of evidence-based target ranking, and it is also one of the more frequently underweighted. Here is how pathway context factors into the Avenzo ranking model and why it changes which candidates make it to the top of the list.
What Pathway Context Evidence Actually Is
Pathway context evidence is not the same as the direct evidence for a target itself. Direct evidence says: this target was perturbed, and the tumor cell showed this response. Pathway context evidence says: this target sits in a node of the signaling network where multiple independent lines of evidence converge, the pathway is known to be active in this tumor type, and the surrounding regulatory architecture is consistent with the target having functional importance in the broader circuit.
The sources for pathway context evidence are different from the sources for direct functional evidence. Protein-protein interaction databases capture known physical interactions between the target and its network neighbors. Pathway membership databases assign the target to annotated signaling cascades with known roles in oncogenesis. Co-mutation and co-expression analysis from large tumor genomic datasets can identify targets that tend to be co-altered with known drivers in a non-random way, suggesting functional coupling. Genetic interaction screens identify synthetic lethal relationships that are, by definition, pathway-context-dependent signals.
None of these pathway context signals constitutes functional validation on its own. They are a different class of evidence from direct experimental perturbation data. But they provide a network-level interpretation frame that can substantially change how directly-observed functional evidence should be read.
When Pathway Context Boosts a Low-Volume Target
Consider a target that appears modest in a volume-based ranking: relatively few published papers, limited direct functional validation, modest genomic alteration frequency. In a simple evidence count approach, this target ranks low. When you add pathway context to the picture, the interpretation can change materially.
If the target sits at a convergence point for multiple known oncogenic pathways in the relevant tumor type, if multiple independent computational approaches identify it as a high-centrality node in the tumor-type-specific signaling network, and if its pathway neighbors are consistently co-altered in the tumor cohort genomic data, then the low direct evidence volume reflects a gap in experimental attention, not a negative finding. The target has not been well-studied; it has not been shown to be unimportant. That is a different situation from a target that has been well-studied and shown inconsistent or negative results.
This kind of reranking happens in our analyses. Targets that rank in the middle of the list on direct evidence volume move up when pathway context is incorporated, because the network signals are consistently pointing toward their relevance. For a discovery team, this surfaces candidates that merit experimental attention but might have been deprioritized based on literature volume alone.
When Pathway Context Penalizes a High-Volume Target
The reverse also occurs. A target with substantial direct evidence literature, high citation count, and a well-known role in oncology biology, can look weaker when pathway context is analyzed explicitly.
The scenario where this matters most is compensatory pathway architecture. If a target's downstream effectors are also served by multiple parallel pathway inputs that remain active when the primary target is inhibited, the network context suggests that inhibiting the target alone may be insufficient to produce a durable tumor response. The direct evidence for the target's functional role may be strong. The pathway context suggests that this functional role is accompanied by a high probability of resistance through compensatory activation. A target in that architecture requires a different development hypothesis than one where pathway context is clean and compensatory inputs are limited.
We flag this pattern in the Avenzo output as a pathway architecture caveat, distinct from the evidence quality assessment. It does not disqualify the target, but it changes the scientific discussion that should happen before first-assay commitment.
How We Score Pathway Context
In the Avenzo model, computational signal convergence is one of the three scoring dimensions, and pathway context is the primary content of that dimension. We score convergence by counting the number of independent computational evidence types that point toward the target: network centrality in curated pathway databases, co-alteration signals from tumor genomic cohorts, genetic interaction predictions from published screens, and expression co-regulation with known pathway members in tumor versus normal tissue.
The convergence scoring uses a tier structure analogous to the preclinical evidence tier structure. A target with convergent support from three or more orthogonal computational evidence types scores higher in this dimension than one supported by a single computational database entry. Independence matters for the same reason it matters in experimental evidence: multiple independent signals pointing the same direction carry more weight than repeated confirmation through a single method.
The pathway context score does not replace the direct functional evidence score. A target that ranks high on pathway context convergence but has no direct in-vivo functional evidence is a hypothesis that merits experimental follow-up, not a validated target. We keep the dimensions separate in the output precisely so a team can see the full picture: strong pathway context combined with thin direct evidence tells a different story than strong pathway context combined with strong direct evidence.
The Boundary: What Pathway Analysis Cannot Tell You
Pathway context evidence is curated from databases and literature that reflect our current knowledge of signaling networks. That knowledge is incomplete and, in some tumor types, substantially incomplete. Novel oncogenic pathways and previously uncharacterized signaling relationships are not captured in current pathway databases by definition.
This means that pathway context evidence is more informative for target candidates in well-studied tumor biology contexts than in less-studied or novel contexts. For a target in pancreatic ductal adenocarcinoma, where the major oncogenic pathway architecture is extensively characterized, pathway context evidence is relatively informative. For a rare tumor type where the oncogenic signaling network has received limited experimental attention, the pathway context analysis is more limited by incomplete database coverage.
We are transparent about this limitation in the output. The computational signal dimension includes source coverage indicators that show how much of the pathway context evidence is derived from densely curated sources versus sparser database entries. For tumor contexts where pathway coverage is thin, the computational dimension should be weighted less heavily in the overall interpretation, and we note this in the analysis.
If you are evaluating targets where pathway architecture context feels like it should be informing the ranking but is not getting explicit treatment in your current synthesis process, the Avenzo platform is designed to surface that dimension alongside the direct evidence picture. Reach out to see what the analysis looks like for your specific target list.